President, Chief Executive Officer, and Director
Mark McLaughlin has an extensive business background and financial expertise. With 10 years as an investment advisor at Lehman Brothers and 3 years at Oppenheimer & Company, Mr. McLaughlin gained experience across raising capital and business development.
Thereafter, Mr. McLaughlin teamed up to manage money with Chris Cadbury, as a 50% Partner in Cadbury Asset Management, utilizing the proprietary indicators of Mr. Cadbury.
Mr. Cadbury’s market indicators were ranked number one in the U.S. by Timer Digest for 2002 and 2011. Mr. McLaughlin continues to collaborate with Mr.Cadbury. Prior to becoming the CEO of ImmuDyne in 2011, Mr. McLaughlin played an integral role in successfully prosecuting several IP violations in ImmuDyne’s favor, as well as streamlining and improving the Company’s operating efficiencies to properly position the Company as It commercializes Its technologies. Mr. McLaughlin is a graduate of Holy Cross, Worcester, MA
Sven Rohmann, MD, PhD, MBA
Global Chief Medical Office, Director
Dr. Sven Rohmann has an excellent track record across the scientific, academic, clinical practice, and commercial areas of the industry. He spent 10 years at Merck Serono where he gained a strong foothold in the pharmaceutical industry. During his tenure at Merck, he was involved in the successful licensing of Erbitux from ImClone and the establishment of Merck Oncology. Dr. Rohmann is a leading expert in innate immunity.
In addition to his clinical expertise, he has worked across product development and marketing, as well as business development for immune health products. E.g. he was part of the management team of Biotec Pharmacon ASA, a public Norwegian company that developed soluble yeast beta-glucan for oncology indications and wound care. In 2010, Dr. Rohmann became the General Manager for Europe at Burrill & Company.
He also serves on the board or in other executive functions for several small-sized companies in Europe and the USA. Prior to joining Burrill & Company, Dr. Rohmann worked as Venture Capital Fund Manager for Novartis Pharma AG, and as Managing Partner and General Partner at Nextech Venture AG. In addition, Dr. Rohmann served as CEO, CBO and CMO of five European biotech start-ups and gained board experience at several SME's in Europe and the USA. Dr. Rohmann offers a unique blend of scientific, pharmaceutical, biotech, and venture capital knowledge.
He has an extensive global network of contacts among health care providers as well as academic and government research administrators. His thorough knowledge of European research and regulatory policies combined with his global network provides great value to IMMUDYNE, allowing the company to expand its research activities and product portfolio globally. Dr. Rohmann received his Medical Degree from the University of Mainz, Germany, and his PhD from the Erasmus University, Rotterdam, Netherlands.
Joseph V. DiTrolio, MD
Chief Medical Officer - U.S. and Director
Joseph V. DiTrolio, MD, isa Diplomate of the American Board of Urology, a Clinical Professor of Surgery, Division of Urology at New Jersey Medical School, the Treasurer, Board of Governors for the Stone Center of New Jersey, and the immediate past Chairman of the Department of Urology for the St. Barnabas Medical Center Healthcare System.
Dr. DiTrolio has served as a medical consultant for Fortune 500 Healthcare companies including Novartis, Sanofi-Aventis, AstraZeneca, Allergan, et al. He is also the current Medical Director for OneMedPlace. He is the holder of several patents.
Dr. DiTrolio’s experience across patient care, clinical research, and new product development brings great value to IMMUDYNE as the Company prepares to rollout new dietary supplement product lines through physician networks and practices. Dr. DiTrolio is a graduate of the University of Richmond, University of Paris, Sorbonne. He received his Medical Degree from New Jersey Medical School.
Chief Operating Officer and Chief Technology Officer
Mr. Galluppi has an extensive background in direct to consumer marketing. In addition to building proprietary technology to facilitate and optimize advertising campaigns for maximum efficiency and profitability. Mr. Galluppi was also instrumental in helping create the framework for an optimal back-end office infrastructure which supported multiple National TV direct response advertising campaigns rated among the top 10 on the national TV IMS report rankings for performance.